Want to see QNTM full AI Analyst Report?
Top Page
Quantum Biopharma
(NASDAQ:QNTM)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.50
▲(6.71% Upside)
Action:N/A
Date:09/22/26
The score is held down primarily by weak financial performance: no revenue, substantial ongoing losses, and persistent cash burn with declining equity that elevates financing risk. Technicals provide some offset with improving short-term trend and positive MACD, but valuation is difficult to justify given negative earnings and no dividend support.
Positive Factors
Lucid-MS regulatory advancement
FDA clearance moves Lucid-MS into a controlled Phase 2 study, materially advancing Quantum’s lead asset toward clinical validation. Its neuroprotective, non-immunomodulatory approach targets an area of high unmet need and could strengthen the company’s strategic position if clinical results support efficacy.
Negative Factors
Pre-revenue and loss-making model
Quantum has not yet established commercial revenue to offset research and corporate costs, while substantial losses continue across reported periods. The business therefore depends on successful clinical development and future financing rather than operating scale, making profitability highly dependent on pipeline execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Lucid-MS regulatory advancement
FDA clearance moves Lucid-MS into a controlled Phase 2 study, materially advancing Quantum’s lead asset toward clinical validation. Its neuroprotective, non-immunomodulatory approach targets an area of high unmet need and could strengthen the company’s strategic position if clinical results support efficacy.
Read all positive factors
Quantum Biopharma (QNTM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.20M
Dividend YieldN/A
Average Volume (3M)204.99K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth56.35%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.65
Shares Outstanding8,087,479
10 Day Avg. Volume186,062
30 Day Avg. Volume204,986
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.47
Price to Sales (P/S)0.00
P/FCF Ratio-2.86
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.85
Revenue Forecast (FY)N/A
Quantum Biopharma Business Overview & Revenue Model
Company Description
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflam...
Quantum Biopharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -250.78K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.66M | -25.79M | -14.38M | -15.72M | -22.12M | -29.82M |
| Net Income | -24.89M | -26.18M | -14.20M | -17.90M | -23.61M | -35.29M |
Balance Sheet | ||||||
| Total Assets | 14.37M | 11.14M | 17.12M | 17.47M | 38.41M | 62.96M |
| Cash, Cash Equivalents and Short-Term Investments | 9.73M | 6.17M | 7.20M | 3.51M | 17.00M | 35.42M |
| Total Debt | 962.16K | 1.87M | 824.92K | 339.20K | 516.42K | 555.90K |
| Total Liabilities | 8.29M | 6.05M | 6.68M | 4.57M | 7.87M | 8.83M |
| Stockholders Equity | 7.94M | 6.91M | 11.48M | 13.24M | 30.54M | 54.13M |
Cash Flow | ||||||
| Free Cash Flow | -5.42M | -8.38M | -6.88M | -10.83M | -28.70M | -21.25M |
| Operating Cash Flow | -5.42M | -8.38M | -6.88M | -10.83M | -28.33M | -20.75M |
| Investing Cash Flow | -3.43M | -1.99M | -1.50M | -269.58K | 12.12M | 268.96K |
| Financing Cash Flow | 10.99M | 6.21M | 11.62M | -3.13M | -2.07M | 38.21M |
Quantum Biopharma Technical Analysis
Positive
3.28
Price Trends
3.26
Positive
4.09
Negative
4.65
Negative
Market Momentum
0.10
Negative
58.59
Neutral
71.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNTM, the sentiment is Positive. The current price of 3.28 is below the 20-day moving average (MA) of 3.33, above the 50-day MA of 3.26, and below the 200-day MA of 4.65, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 58.59 is Neutral, neither overbought nor oversold. The STOCH value of 71.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QNTM.
Quantum Biopharma Risk Analysis
Quantum Biopharma disclosed 1 risk factors in its most recent earnings report. Quantum Biopharma reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quantum Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | C$29.90M | -6.03 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $29.20M | -0.65 | -413.07% | ― | ― | 56.35% | |
44 Neutral | C$10.71M | -8.15 | -19.37% | ― | -19.20% | 42.54% | |
42 Neutral | C$51.29M | -0.76 | -2099.75% | ― | -100.00% | 94.43% | |
41 Neutral | C$10.28M | -2.94 | 28.59% | ― | 0.90% | 57.73% | |
41 Neutral | C$14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
QNTM
Quantum Biopharma
3.70
-13.43
-78.40%
TSE:ATLE
Willow Biosciences Inc
0.11
-0.06
-33.33%
TSE:LABS
MediPharm Labs
0.07
0.00
0.00%
TSE:PCLO
PharmaCielo
0.06
0.01
22.22%
TSE:AVCN
Avicanna
0.11
-0.15
-58.00%
TSE:INNO
InnoCan Pharma
2.38
-11.02
-82.24%
Quantum Biopharma Corporate Events
Quantum BioPharma Highlights Year of Financing Moves, Debt Settlement and Governance Changes
Sep 17, 2026
In a series of announcements spanning March 2025 to August 2026, Quantum BioPharma undertook multiple capital markets and governance actions, including cancelling director Michael Zapolin’s 7,692 warrants on March 7, 2025 and replacing them ...
Quantum BioPharma Gains Rodman & Renshaw BUY Rating and US$8 Target
Sep 17, 2026
On September 17, 2026, Quantum BioPharma announced that investment bank Rodman Renshaw has initiated equity research coverage on the company with a BUY rating and a US$8 price target. The unpaid coverage, led by Director of Research and Senior Bi...
Quantum BioPharma Showcases FDA-Backed Lucid-MS Program at Toronto Growth Summit
Sep 15, 2026
On September 15, 2026, Quantum BioPharma announced it will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, scheduled for September 16, 2026 at the Sheraton Centre Toronto Hotel. Co-founder and Executive Co-chairman Antho...
Quantum BioPharma Boosts Liquidity as FDA Clears Pivotal Lucid-MS Phase 2 Trial
Aug 14, 2026
Quantum BioPharma reported second-quarter 2026 results on August 14, 2026 that show a markedly stronger balance sheet and improved liquidity. Cash, cash equivalents and digital assets rose to US$9.5 million as of June 30, 2026, nearly double year-...
Quantum Biopharma Posts Higher Assets and Losses in Q2 2026 Filing
Aug 13, 2026
Quantum Biopharma Ltd. filed a Form 6-K on August 13, 2026, reporting unaudited condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended June 30, 2026 and 2025. The filing shows ...
Quantum BioPharma Wins FDA Green Light for Phase 2 Lucid-MS Trial in Progressive Multiple Sclerosis
Aug 10, 2026
On August 10, 2026, Quantum BioPharma announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Lucid-MS, allowing the company to proceed to a randomized, double-blind, placebo-controlled Phase 2 tri...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.